<DOC>
	<DOCNO>NCT02279173</DOCNO>
	<brief_summary>This phase 3b single arm , open label , multicenter study describe percentage time pediatric subject ITP platelet response receive romiplostim , define platelet count ≥ 50 x 10^9/L absence ITP rescue medication past 4 week .</brief_summary>
	<brief_title>Single Arm , Open-label , Long-term Study Romiplostim Thrombocytopenic Pediatric Subjects With ITP .</brief_title>
	<detailed_description>This phase 3b single arm , open label , multicenter study describe percentage time pediatric subject ITP platelet response receive romiplostim , define platelet count ≥ 50 x 10^9/L absence ITP rescue medication past 4 week . This protocol provide open label romiplostim thrombocytopenic pediatric subject ITP diagnose least 6 month receive least 1 prior ITP therapy ( exclude romiplostim ) ineligible ITP therapy .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Diagnosis primary ITP accord The American Society Hematology ( ASH ) Guidelines ( Neunert et al , 2011 ) least 6 month screen , regardless splenectomy status Age ≥ 1 year &lt; 18 year age Refractory prior ITP therapy , relapse prior ITP therapy , ineligible therapy Examples prior therapy include : corticosteroid , IVIG , antiD immunoglobulin , platelet transfusion . Platelet count ≤ 30 x10^9/L experience uncontrolled bleeding Has provide inform consent studyspecific procedure ; Adequate hematologic , renal , liver function screen Hemoglobin &gt; 10.0 g/dL Serum creatinine ≤ 1.5 x ULN Total serum bilirubin ≤ 1.5 x ULN AST ALT ≤ 3.0 x ULN History bone marrow stem cell disorder ( Any abnormal bone marrow finding typical ITP must approve Amgen subject may enrol ) Prior bone marrow transplant peripheral blood progenitor cell transplant Active prior malignancy except nonmelanoma skin cancer within last 5 year History myelodysplastic syndrome History bleed diathesis History congenital thrombocytopenia History HepB , HepC HIV History systemic lupus erythematosus , Evans syndrome , autoimmune neutropenia History antiphospholipid antibody syndrome know positive lupus anticoagulant History disseminate intravascular coagulation , hemolytic uremic syndrome , thrombotic thrombocytopenic purpura History venous thromboembolism thrombotic event Previous use romiplostim previous use eltrombopag within 4 week enrollment Previous use PEGrHuMGDF , recombinant human thrombopoietin ( rHuTPO ) platelet produce agent Rituximab ( indication ) 6mercaptopurine within 8 week enrollment , anticipate use time study Splenectomy within 4 week screen visit Alkylating agent within 8 week screen visit anticipate use time propose study Vaccinations know decrease platelet count within 8 week screen visit Currently enrol another investigational device drug study , less 30 day since end investigational study Will investigational procedure enrol study Female subject child bear potential ( define first menses ) willing use , combination partner highly effective method birth control treatment 1 month end treatment Subject pregnant breast feeding , might become pregnant within 1 month end treatment Subject know hypersensitivity recombinant Escherichia coli derive product ( eg , Infergen® , Neupogen® , somatropin , Actimmune® ) Has previously enrol study Will available protocolrequired study visit procedure , best subject 's investigator 's knowledge Any kind disorder , may compromise subject give write informed consent and/or comply require study procedure</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Immune Thrombocytopenia ( ITP )</keyword>
	<keyword>Amgen</keyword>
</DOC>